Akari Therapeutics, Statistics
Total Valuation
AKTX has a market cap or net worth of $43.44 million. The enterprise value is $42.70 million.
Market Cap | 43.44M |
Enterprise Value | 42.70M |
Important Dates
The last earnings date was Thursday, May 15, 2025, before market open.
Earnings Date | May 15, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
AKTX has 32.18 million shares outstanding. The number of shares has increased by 202.84% in one year.
Current Share Class | n/a |
Shares Outstanding | 32.18M |
Shares Change (YoY) | +202.84% |
Shares Change (QoQ) | +40.63% |
Owned by Insiders (%) | 45.73% |
Owned by Institutions (%) | 0.97% |
Float | 17.06M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 1.69 |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.16, with a Debt / Equity ratio of 0.08.
Current Ratio | 0.16 |
Quick Ratio | 0.12 |
Debt / Equity | 0.08 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -47.43 |
Financial Efficiency
Return on equity (ROE) is -197.11% and return on invested capital (ROIC) is -88.47%.
Return on Equity (ROE) | -197.11% |
Return on Assets (ROA) | -33.00% |
Return on Invested Capital (ROIC) | -88.47% |
Return on Capital Employed (ROCE) | -47.19% |
Revenue Per Employee | n/a |
Profits Per Employee | -$1.99M |
Employee Count | 9 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -25.70% in the last 52 weeks. The beta is 0.29, so AKTX's price volatility has been lower than the market average.
Beta (5Y) | 0.29 |
52-Week Price Change | -25.70% |
50-Day Moving Average | 1.30 |
200-Day Moving Average | 1.80 |
Relative Strength Index (RSI) | 53.61 |
Average Volume (20 Days) | 14,771 |
Short Selling Information
Short Interest | 118,286 |
Short Previous Month | 110,565 |
Short % of Shares Out | 0.57% |
Short % of Float | n/a |
Short Ratio (days to cover) | 3.89 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -14.18M |
Pretax Income | n/a |
Net Income | -17.93M |
EBITDA | -14.18M |
EBIT | -14.18M |
Earnings Per Share (EPS) | -$1.05 |
Balance Sheet
The company has $2.58 million in cash and $1.85 million in debt, giving a net cash position of $736,000 or $0.02 per share.
Cash & Cash Equivalents | 2.58M |
Total Debt | 1.85M |
Net Cash | 736,000 |
Net Cash Per Share | $0.02 |
Equity (Book Value) | 21.75M |
Book Value Per Share | 0.80 |
Working Capital | -17.56M |
Cash Flow
Operating Cash Flow | -10.66M |
Capital Expenditures | n/a |
Free Cash Flow | -10.66M |
FCF Per Share | -$0.33 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
AKTX does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -202.84% |
Shareholder Yield | -202.84% |
Earnings Yield | -41.28% |
FCF Yield | -24.54% |
Analyst Forecast
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on August 17, 2023. It was a reverse split with a ratio of 0.05:1.
Last Split Date | Aug 17, 2023 |
Split Type | Reverse |
Split Ratio | 0.05:1 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |